cytes, 38% neutrophils, 3% eosinophils, 3% basophils, 1% monocytes, 3% lymphocytes; hemoglobin, 10.2 g/dl; platelet count, 91 Â 10 9 /l. The prognostic Sokal (1.09) and Hasford
(862.6) scores were of intermediate risk. Cytogenetic and fluorescence in situ hybridization analyses showed the presence of t(9;22)(q34;q11) and BCR-ABL fusion gene in 100% of bone marrow metaphases.
RT-PCR analysis for BCR-ABL mRNA was performed using primers enabling the detection of transcripts with e13a2, e14a2 and e1a2 BCR-ABL junctions. RT-PCR with e13a2/e14a2 primers was negative, whereas with e1a2 primers, an aberrant band of high molecular weight (41 kb) was observed ( Figure 1a ). Sequencing revealed that this band corresponded to a junction between BCR exon e8 and ABL exon a2 including a 46-nucleotide stretch from BCR intron 8 at the fusion point (U07000 in GenBank, bases 108153-108198). This neo-exon in the BCR intron 8 is defined by cryptic donor and acceptor splice sites (Figure 1b) . Using a new forward BCR e8 primer (5 0 -TCAATGAGGAGATCACACCCC-3 0 ) and the ABL a2 reverse primer, 2 we amplified a single fragment of expected size (173 bp) corresponding to this e8a2 transcript ( Figure 1a ).
The splicing of BCR exon 8 to ABL exon 2 would not produce an oncogenic BCR-ABL protein due to a generation of a premature stop codon. 1 In previously reported cases, the reading frame of e8a2 mRNA was correctly maintained by an insertion of intronic sequences generally derived from the ABL intron Ib or by breakpoints within the BCR exon 8. In the present case, a neo-exon from BCR intron 8 was spliced between BCR exon e8 and ABL exon 2, giving rise to an in-frame e8a2 BCR-ABL transcript. The recognition of these cryptic splicing sites, which are never used in the wild-type BCR gene, might simply result from new properties of the chimeric DNA fragment acquired during the reorganization of a neo-intron formed by BCR intron 8 and ABL intron 1. It is also possible that a second event such as a particular polymorphism or mutation activated one splicing enhancer in the vicinity of this neo-exon or altered the properties of a splicing factor that would able to recognize these particular splice sites with good efficiency. Overall, translocation breakpoints generating e8a2 fusions may be very infrequent or, in contrast, may occur relatively frequently, but as they lead to a truncated BCR-ABL protein, only rare CML cases that express in-frame e8a2 transcripts are detected.
Clinically, e8a2-positive CML patients have no distinctive features at diagnosis. 1 In contrast to other reported patients with e8a2 BCR-ABL, who had a trend toward thrombocytosis, our patient presented with thrombocytopenia. Thrombocytopenia is occasionally found in untreated chronic phase CML. The mechanism is not clear, but it might be presumed that leukemia cells do not differentiate into the megakaryocytic lineage while normal progenitors are inhibited. 3 Imatinib at standard dosage induced in the patient a complete hematological remission after 1 month of treatment, including normalization of the platelet count (277 Â 10 9 /l). A complete cytogenetic response was demonstrated at 9 months after the start of treatment. Molecular monitoring was performed using real-time RT-PCR with the BCR e8 primer, ABL primers and probe. 4 The BCR-ABL/ABL ratio in blood cells was 93.1% at diagnosis, 63.4% after 3 months, 0.037% after 9 months and 0.022% after 12 months of therapy. Thus, the patient has achieved a major molecular response (BCR-ABL/ABL ratio o0.05%) within the first year of treatment, which is strongly predictive of a durable cytogenetic remission. 5 Previously reported patients with e8a2 transcripts were resistant to interferon-alpha treatment, suggesting a worse prognosis of CML with e8a2 BCR-ABL.
1 Our case provides evidence that e8a2 CML may be sensitive to the ABL tyrosine kinase inhibitor imatinib. More clinical observations and, perhaps, experimental studies of the protein translated from e8a2 BCR-ABL mRNA in a murine model may help to assess its leukemogenic activity and a possible influence on clinical course and outcome. Recently, a point mutation in the Janus kinase 2 gene (JAK2) was identified in several chronic myeloid disorders, most frequently in polycythemia vera (PV) (65-97%), essential thrombocythemia (ET) (23-57%) and chronic idiopathic myelofibrosis (CIM) (35-57%) (see Table 1 ). The mutation is 1849G4T, resulting in substitution of phenylalanine for valine (V617F) in the protein. To our knowledge, this mutation has not been reported in normal patients, those with reactive myeloid cell cytoses or those with chronic myelogenous leukemia (CML), but has been found in a small proportion of patients with chronic neutrophilic leukemia, hypereosinophilic syndrome, systemic mast cell disease, mixed chronic myeloproliferative disorder/myelodysplastic syndrome (CMPD/MDS), MDS and AML. [1] [2] [3] [4] [5] [6] [7] The mutation has also not been found in precursor B or T acute lymphoblastic leukemia (ALL) or B-cell chronic lymphocytic leukemia. 6, 7 Since the common non-CML chronic myeloid disorders are frequently difficult to diagnose due to considerable clinicopathologic overlap with reactive cytoses, a simple clinical assay for JAK2 V617F mutation detection would be quite useful. In the articles published to date, a variety of sample types and detection methods were used, but as described, none seemed ideally suited for a busy clinical laboratory in which cost, equipment availability, assay turn-around-time, sample type and daily sample volumes are of practical importance. We have designed and validated two JAK2 V617F mutation assays that use genomic DNA extracted from 0.5-1 ml of whole blood or bone marrow aspirate specimens and both are suitable for routine clinical laboratory testing.
The first assay uses allele-specific polymerase chain reaction (PCR) (designated as the AS-PCR assay) and was designed for maximum sensitivity (0.01-0.1%). Briefly, a mutation-specific forward primer is used in a PCR reaction with a wild-type sequence reverse primer containing a fluorescent tag. Only mutated DNA will be amplified, if present, and the PCR reaction product is analyzed using capillary electrophoresis in an automated genetic analyzer. Primer design and representative results are shown in Figure 1 .
The second assay (designated as the melting curve assay), was designed to be very simple, rapid and inexpensive and has moderate sensitivity (1-10%). Briefly, a short fragment of genomic DNA spanning the mutation site is amplified using PCR in a real time PCR machine. Two fluorescent hybridization probes are also present in the reaction and used for melting curve analysis following completion of the PCR reaction. The probes bind within one base pair of each other during the melting curve evaluation, allowing emission of fluorescence that can be detected by the instrument. One probe spans the mutation site and contains the wild-type sequence, causing it to bind more firmly to the PCR product with the wild-type sequence than to the PCR product containing the point mutation. As the temperature is continuously raised in the melting step, the probes dissociate from the PCR product and the dissociation is seen as a decrease in fluorescence. Probe bound across a mismatch dissociates at 551C while probe bound across wild-type sequence dissociates at 651C allowing the mutated and wild-type amplified DNA to be distinguished. Primer and probe design and representative results are shown in Figure 2 .
The assays were validated using clinical samples retrieved from the Mayo Clinic hematopathology practice with IRB approval. These included blood and/or bone marrow aspirate specimens from the following patient groups: self-identified Letters to the Editor normals (n ¼ 48), reactive myeloid cytoses (n ¼ 6), PV (n ¼ 18), essential thrombocythemia (n ¼ 5), CIM (n ¼ 11), CML (n ¼ 12), chronic eosinophilic leukemia (n ¼ 1), systemic mast cell disease (n ¼ 6), CMPD not otherwise specified (CMPD-NOS) (n ¼ 1), chronic myelomonocytic leukemia (n ¼ 6), mixed CMPD/MDS (n ¼ 3), T-cell large granular lymphocyte leukemia (n ¼ 16) and mycosis fungoides/sezary syndrome (n ¼ 30). In addition, freshly frozen solid tissue samples from the following B-cell neoplasms were evaluated: B-cell acute lymphoblastic leukemia (n ¼ 5), B-cell chronic lymphocytic leukemia (n ¼ 18), mantle cell lymphoma (n ¼ 12), follicular lymphoma (n ¼ 22), splenic marginal zone lymphoma (n ¼ 11), extranodal marginal zone B-cell lymphoma (n ¼ 1) and lymphoplasmacytic lymphoma (n ¼ 6). Cell dilutions of JAK2 V617F positive and negative cell lines were used to determine the analytical sensitivity of each assay. Both assays showed excellent intra-run and inter-run reproducibility.
The clinical sensitivity and specificity data is shown in Table 1 . For each sample, concordant results were obtained using the two assays and the frequency of mutation detection in each diagnostic subgroup was similar to that previously reported in the literature (Table 1) . The results greatly expand the literature reporting the absence of JAK2 V617F mutations in lymphoid neoplasms. This is important in the clinical setting, where it is not uncommon for patients with CMPDs to have coexisting lymphoid neoplasm or for patients with lymphoid neoplasms to have reactive myeloid components simulating early CMPD.
It is not entirely clear how sensitive on assay needs to be for maximal clinical sensitivity using whole blood or bone marrow specimens, the preferred specimens for routine clinical analysis. Many of the initial studies were performed using isolated neutrophils or other presorted sample fractions and the true frequencies of the JAK2 mutation in the various myeloid lineages in each disease category are not yet known. It is theoretically possible that a low sensitivity assay could give a false negative result if there are a large number of contaminating nonneoplastic cells (such as lymphocytes) present or if the mutation is confined to only some myeloid cell lines or only subsets of positive lineages. In one previous study, 2 a dramatic increase in mutation detection was observed using an allele-specific PCR technique (analytical sensitivity quoted as 3%) rather than direct sequencing (sensitivity 20-30%) when testing purified blood granulocytes. It was suggested that the mutation may be present in only a subset of neutrophils in some cases. Owing to these concerns, we developed the AS-PCR assay (sensitivity up to 0.01%), which gives the best sensitivity for point mutation detection of the methods available in most clinical laboratories. In our experience, the vast majority of samples that would be candidates for JAK2 mutation testing have the myeloid lineage cells of interest present in either blood or bone marrow at a level greater than 0.01%. The AS-PCR assay did not show any increase in detection sensitivity when compared with the less sensitive melting curve assay for the group of patient samples tested. In addition, for eight positive and four negative samples, neutrophils were isolated and tested by both methods as well as direct sequencing with 100% concordant results for all three assays. There is also the theoretical possibility that a low sensitivity assay could give false negative results in blood samples if the mutation is confined to erythroid and/or megakaryocyte lineages, since circulating red blood cells and platelets contain no DNA. To evaluate this possibility, 15 paired blood and bone marrow samples were evaluated with 100% concordant results. These samples were from the following disease types: PV-3, CIM-4, CMPD-NOS-1, systemic mast cell disease-3, CMML-2 and CMPD/MDS-2. The group contained seven positive and eight negative samples. It appears, therefore, that in the majority of cases (1) DNA from whole blood and bone marrow aspirate specimens is adequate for testing with no preanalytical cell sorting/purification required (2) an analytical sensitivity of 1-10% is adequate and (3) blood and bone marrow aspirate specimens are equivalent for the purposes of this mutation detection. However, more data regarding the distribution of the JAK2 mutation in the diseases being evaluated are needed to determine whether these assays might miss a small number of positive cases.
In summary, simple and reliable assays for detection of JAK2 V617F mutations are needed, and we have found both assays described here to be very suitable for the clinical laboratory setting. 
